Replies to post #221320 on Biotech Values

[DewDiligence]

ABUS 3Q18 results—cash=$142M:

https://finance.yahoo.com/news/arbutus-reports-2018-third-quarter-210100483.html

[DewDiligence]

ABUS starts phase-1 trial of AB-729 for HBV:

https://www.globenewswire.com/news-release/2019/06/20/1871749/0/en/Arbutus-receives-regulatory-clearance-to-initiate-Phase-1a-1b-Clinical-Trial-of-AB-729.html

AB-729 is an RNAi-based HBV-replication inhibitor; it should not be confused with AB-506, ABUS’ HBV “core” inhibitor that is already in phase-1 and will have an initial data readout this summer.